Effects of carbamazepine on cerebrospinal fluid somatostatin

Psychopharmacology (Berl). 1985;85(2):210-3. doi: 10.1007/BF00428416.

Abstract

This paper reports the reduction of the concentration of the neuropeptide somatostatin in the CSF of patients with affective illness during treatment with the anticonvulsant carbamazepine. None of the other psychotropic agents used in this study similarly affected CSF somatostatin, although zimelidine appeared to increase CSF somatostatin in a small number of patients. The potential mechanism and significance of the effects of carbamazepine on CSF somatostatin are discussed in relation to the psychotropic, anticonvulsant, and analgesic properties of carbamazepine.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adrenocorticotropic Hormone / metabolism
  • Bipolar Disorder / cerebrospinal fluid
  • Bipolar Disorder / drug therapy*
  • Carbamazepine / pharmacology
  • Carbamazepine / therapeutic use*
  • Depressive Disorder / cerebrospinal fluid
  • Depressive Disorder / drug therapy*
  • Humans
  • Hypothalamo-Hypophyseal System / drug effects
  • Norepinephrine / physiology
  • Somatostatin / cerebrospinal fluid*
  • gamma-Aminobutyric Acid / physiology

Substances

  • Carbamazepine
  • Somatostatin
  • gamma-Aminobutyric Acid
  • Adrenocorticotropic Hormone
  • Norepinephrine